Monday, 25 July 2022

NATCO Announces Approval of its ANDA for Cabazitaxel Intravenous Solution

NATCO Announces Approval of its ANDA for Cabazitaxel Intravenous Solution
NATCO Announces Approval of its ANDA for Cabazitaxel Intravenous Solution

Natco Pharma Limitedannounces that the U.S. Food and Drug Administration has granted approval to its partner Breckenridge Pharmaceutical Inc’s Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit) for the 60mg/1.5mL (40mg/mL) strength.

admin Mon, 07/25/2022 - 17:03

source https://www.pharmatutor.org/pharma-news/2022/natco-announces-approval-of-its-anda-for-cabazitaxel-intravenous-solution

No comments:

Post a Comment

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...